


FDA Approves The Acufocus IC-8 Small Aperture IOL For Cataract Surgery



AcuFocus Inc. on July 25, 2022 announced the FDA has approved its IC-8 Aphera IOL for the treatment of cataracts. The Aphera IOL is the first and only non-toric extended depth of focus IOL approved for the 82% of cataract patients who have as much as 1.5 D of corneal astigmatism.

Al Waterhouse, president and CEO for AcuFocus, said the company was pleased to receive FDA approval for the IOL.

“The Aphera IOL represents several firsts for surgeons and patients: the first small aperture IOL to receive FDA approval, the first lens indicated for implantation with a monofocal or monofocal toric IOL in the fellow eye, the first extended depth of focus lens indicated for monovision, and the first non-toric IOL indicated for cataract patients with low amounts of corneal astigmatism,” Waterhouse said in a news release.

Most patients receive a monofocal IOL at the time of cataract surgery. While monofocal lenses provide excellent distance vision, objects up close remain blurry. Other available presbyopia-correcting lens designs have complex optics that split, shift, or stretch light to provide clear vision at more than one discrete focal point. In contrast, the Aphera IOL, with its proprietary small aperture technology, seamlessly provides excellent distance vision as well as clear intermediate and near vision, effectively mitigating the effects of presbyopia.

“The Aphera IOL is the first lens design, with its embedded FilterRing component, to

mitigate the effects of presbyopia by simply filtering out peripheral defocused and aberrated light that degrades image quality,” Vance Thompson, MD of Vance Thompson Vision, Sioux Falls, South Dakota, said in a news release.

Aphera IOL subjects achieved equivalent uncorrected distance vision and statistically superior intermediate and near vision compared to control subjects. Aphera IOL subjects also achieved comparable binocular contrast sensitivity to control subjects in both photopic and mesopic conditions, a first reported for an extended depth of focus lens.

We look forward to the prospect here at Mann Eye Institute to offer the AcuFocus IC-8 lens to your patients. Furthermore, we appreciate the opportunity to bring new technology to your patients and want both you and your patients to be happy and confident with the care they receive.